Replacement of Nebulised Ipratropium With Inhaled Tiotropium in Stable Chronic Obstructive Pulmonary Disease (COPD)

• Status: Withdrawn
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Some patients with chronic obstructive pulmonary disease (COPD) take nebulised treatments to ease the symptom of breathlessness, including the drug ipratropium. Nebulised bronchodilator drugs are taken up to 4 times through the day, and this can take up to 15 minutes each time. Although the treatment isbe effective, patients report that the time taken to set-up and use the nebuliser can be a disincentive to regular use. By contrast, an inhaler device is easy to use following appropriate instruction, and takes only a few seconds to administer. Inhaled tiotropium is a once daily treatment taken by inhaler which has been shown to be effective in COPD. We wish to assess whether inhaled Tiotropium as effective as nebulised ipratropium in patients with stable chronic obstructive pulmonary disease.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: NHS Greater Glasgow and Clyde
• Treatments: Ipratropium; Tiotropium Bromide

Criteria

Inclusion Criteria:

• Stable Moderate to severe COPD (GOLD criteria)

• > 20 pack year smoking history

• current treatment with nebulised ipratropium bromide

• no exacerbations within preceding 3 months

Exclusion Criteria:

• current participation in other study

• < 20 pack year smoking history

• Significant co-morbidity e.g. cardiac

• history of intolerance to lactose